• Home
  • Store
    • Newsletter Subscriptions
    • Multimedia
    • Books
    • eBooks
    • ABPN SA Courses
    • Social Work Courses
  • CME Center
  • Multimedia
    • Podcast
    • Webinars
    • Blog
    • Psychiatry News Videos
    • Medication Guide Videos
  • Newsletters
    • General Psychiatry
    • Child Psychiatry
    • Addiction Treatment
    • Hospital Psychiatry
    • Geriatric Psychiatry
    • Psychotherapy and Social Work
  • FAQs
  • Med Fact Book App
  • Log In
  • Register
  • Welcome
  • Sign Out
  • Subscribe
Home » A Cautionary Consensus on the Use of Ketamine for Depression

A Cautionary Consensus on the Use of Ketamine for Depression

September 1, 2017
Taylor Walker Noriega, PharmD candidate (2018)
From The Carlat Psychiatry Report
Issue Links: Learning Objectives | Editorial Information | PDF of Issue
Taylor Walker Noriega, PharmD candidate (2018) Ms. Noriega has disclosed that she has no relevant financial or other interests in any commercial companies pertaining to this educational activity.

Review of: Sanacora G et al, JAMA Psychiatry 2017;74(4):399–405. doi:10.1001/jamapsychiatry.2017.0080

Ketamine has become increasingly popular as an off-label medication for rapid onset treatment of refractory depression. Recently, the American Psychiatric Association convened a task force to review the data and come up with some recommendations. The task force reviewed seven double-blind, randomized placebo-controlled trials involving a total of 147 depressed patients.

In terms of patient selection, there are no clearly defined parameters regarding which patients are most appropriate for ketamine. Most evidence is in patients with depressive episodes without psychotic features, and the dose most often shown to be effective is 0.5 mg/kg given intravenously (IV) over 40 minutes. For perspective, the anesthesia dose ranges from 1 to 4.5 mg/kg IV. Anecdotally, the authors note that many ketamine clinics administer doses 2–3 times a week for 2–3 weeks and then taper, depending on patient response. One study showed that doses given 3 times weekly were not more effective than doses given twice weekly. Common side effects after infusion include confusion, blurred vision, and poor coordination. Because approximately 30% of patients in three clinical trials experienced a spike in blood pressure over 180/100 mmHg and heart rates over 110 beats per minute, it’s recommended to do basic monitoring (ECG, BP, O2 sat). Patients at a higher risk of complications (those with cardiovascular disease, those on other depressants, and elderly patients) should be treated at a facility equipped to manage cardiorespiratory events.

Some are reporting the use of lower or higher doses of ketamine, intranasal administration instead of IV, or take-home ketamine, but the authors could not find enough evidence in the literature to endorse these practices. For example, the authors describe trials using lower doses (0.1–0.4 mg/kg IV) or intranasal ketamine (50 mg/ml nasal spray), both of which seemed to show less robust efficacy (see TCPR February 2017 for one prescriber’s anecdotal experience using intranasal ketamine).

Another unknown is how long to use ketamine. Response may be fast, but the studies reviewed by these experts showed relapse rates up to nearly 90% just 4 weeks following the ketamine treatment. We have no long-term safety data either, and the authors share concerns of some of the known risks, such as cognitive impairment or abuse.

TCPR’s Take
Overall, the consensus statement makes one thing clear: We need more data. We recommend considering ketamine in severe, refractory, or suicidal depression without psychotic features, at a dose of 0.5 mg/kg IV over 40 minutes. Ketamine may also be useful in patients who are not good candidates for ECT. Though the rapid response is promising, the effects may be transient, and maintenance infusions may be required for some patients, similar to ECT.

 
General Psychiatry
KEYWORDS antidepressants depressive_disorder research-update
    Taylor Walker Noriega, PharmD candidate (2018)

    More from this author
    www.thecarlatreport.com
    Issue Date: September 1, 2017
    SUBSCRIBE NOW
    Table Of Contents
    CME Post-Test - Intellectual Disability, TCPR, September/October 2017
    Psychotherapy for the Intellectually Disabled: The Skills System Approach
    A Cautionary Consensus on the Use of Ketamine for Depression
    Note From the Editor-in-Chief
    Psychopharmacology for Patients With Intellectual Disability
    Interviewing and Evaluating Patients With Intellectual Disability
    DOWNLOAD NOW
    Featured Book
    • MFB7e_Print_App_Access.png

      Medication Fact Book for Psychiatric Practice, Seventh Edition (2024) - Regular Bound Book

      The updated 2024 reference guide covering the most commonly prescribed medications in psychiatry.
      READ MORE
    Featured Video
    • KarXT (Cobenfy)_ The Breakthrough Antipsychotic That Could Change Everything.jpg
      General Psychiatry

      KarXT (Cobenfy): The Breakthrough Antipsychotic That Could Change Everything

      Read More
    Featured Podcast
    • shutterstock_2622607431.jpg
      General Psychiatry

      Should You Test MTHFR?

      MTHFR is a...
      Listen now
    Recommended
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png

    About

    • About Us
    • CME Center
    • FAQ
    • Contact Us

    Shop Online

    • Newsletters
    • Multimedia Subscriptions
    • Books
    • eBooks
    • ABPN Self-Assessment Courses

    Newsletters

    • The Carlat Psychiatry Report
    • The Carlat Child Psychiatry Report
    • The Carlat Addiction Treatment Report
    • The Carlat Hospital Psychiatry Report
    • The Carlat Geriatric Psychiatry Report
    • The Carlat Psychotherapy Report

    Contact

    carlat@thecarlatreport.com

    866-348-9279

    PO Box 626, Newburyport MA 01950

    Follow Us

    Please see our Terms and Conditions, Privacy Policy, Subscription Agreement, Use of Cookies, and Hardware/Software Requirements to view our website.

    © 2025 Carlat Publishing, LLC and Affiliates, All Rights Reserved.